Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Similar articles for PubMed (Select 23665601)

1.

Apparent mineralocorticoid excess (AME) syndrome.

Parvez Y, Sayed OE.

Indian Pediatr. 2013 Apr;50(4):416-8.

2.

Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene.

Coeli FB, Ferraz LF, Lemos-Marini SH, Rigatto SZ, Belangero VM, de-Mello MP.

Arq Bras Endocrinol Metabol. 2008 Nov;52(8):1277-81.

3.

[From gene to disease; 'apparent mineralocorticoid excess' syndrome, a syndrome with an apparent excess of mineral corticoids].

Levtchenko EN, Deinum J, Knoers NV, Hermus AR, Monnens LA, Lenders JW.

Ned Tijdschr Geneeskd. 2007 Mar 24;151(12):692-4. Review. Dutch.

PMID:
17447595
4.

Apparent mineralocorticoid excess syndrome: an overview.

Palermo M, Quinkler M, Stewart PM.

Arq Bras Endocrinol Metabol. 2004 Oct;48(5):687-96. Epub 2005 Mar 7. Review.

6.

Apparent mineralocorticoid excess: report of six new cases and extensive personal experience.

Morineau G, Sulmont V, Salomon R, Fiquet-Kempf B, Jeunemaître X, Nicod J, Ferrari P.

J Am Soc Nephrol. 2006 Nov;17(11):3176-84. Epub 2006 Oct 11.

7.

Apparent mineralocorticoid excess syndrome: report of one family with three affected children.

Al-Harbi T, Al-Shaikh A.

J Pediatr Endocrinol Metab. 2012;25(11-12):1083-8. doi: 10.1515/jpem-2012-0113.

PMID:
23329753
8.

Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.

Atanasov AG, Ignatova ID, Nashev LG, Dick B, Ferrari P, Frey FJ, Odermatt A.

J Am Soc Nephrol. 2007 Apr;18(4):1262-70. Epub 2007 Feb 21.

9.

Apparent mineralocorticoid excess.

Wilson RC, Nimkarn S, New MI.

Trends Endocrinol Metab. 2001 Apr;12(3):104-11. Review.

PMID:
11306334
10.
11.

In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess.

Lin-Su K, Zhou P, Arora N, Betensky BP, New MI, Wilson RC.

J Clin Endocrinol Metab. 2004 May;89(5):2024-7.

PMID:
15126515
12.

[Deficiency of 11beta-hydroxysteroid dehydrogenase type 2 (syndrome of apparent mineralocorticoid excess)].

Mune T.

Nihon Rinsho. 2006 May 28;Suppl 1:651-4. Review. Japanese. No abstract available.

PMID:
16776240
13.

Cortisol metabolism in hypertension.

Hammer F, Stewart PM.

Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. Review.

PMID:
16980198
14.

Apparent mineralocorticoid excess: time of manifestation and complications despite treatment.

Knops NB, Monnens LA, Lenders JW, Levtchenko EN.

Pediatrics. 2011 Jun;127(6):e1610-4. doi: 10.1542/peds.2010-1928. Epub 2011 May 2.

15.

Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state.

Li A, Li KX, Marui S, Krozowski ZS, Batista MC, Whorwood CB, Arnhold IJ, Shackleton CH, Mendonca BB, Stewart PM.

J Hypertens. 1997 Dec;15(12 Pt 1):1397-402.

PMID:
9431844
16.

11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.

Campino C, Carvajal CA, Cornejo J, San Martín B, Olivieri O, Guidi G, Faccini G, Pasini F, Sateler J, Baudrand R, Mosso L, Owen GI, Kalergis AM, Padilla O, Fardella CE.

Endocrine. 2010 Feb;37(1):106-14. doi: 10.1007/s12020-009-9269-9. Epub 2009 Oct 31.

PMID:
19882252
17.

Apparent mineralocorticoid excess manifested in an elderly patient with hypothyroidism.

New MI.

Mt Sinai J Med. 2007 Apr;74(1):40-1. No abstract available.

PMID:
17516565
18.

Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

Li A, Tedde R, Krozowski ZS, Pala A, Li KX, Shackleton CH, Mantero F, Palermo M, Stewart PM.

Am J Hum Genet. 1998 Aug;63(2):370-9.

19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk